Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morgonrapport
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
    • Transkriptioner
    • Inbjudningar till årsstämmor
    • IPOs
  • InderesTV
  • Portfölj
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

The Nomination Committee's proposal for the Board of Directors of Apotea AB (publ)

Apotea
Ladda ner börsmeddelandet

Ahead of the annual general meeting of Apotea AB (publ) (“Apotea”) on May 26, 2026, the Nomination Committee hereby announces its proposal regarding the Chairman of the Board and other members of the Board.

The Nomination Committee proposes that Cecilia Qvist, Anders Eriksson, Monica Lindstedt, Per Schlingmann and Pär Svärdson are re-elected as members of the Board of Directors and that Eva Nilsagård and Johan Lundgren are elected as new members of the Board of Directors of Apotea. Furthermore, the Nomination Committee proposes re-election of Cecilia Qvist as Chairman of the Board. Joanna Hummel left the board on February 4, 2026, to take up an operational role in Apotea. Jonas Hagströmer has informed the Nomination Committee that he declines re-election. The Nomination Committee's proposal means that the number of Board members will remain at seven.

Eva Nilsagård (born 1964) has over 30 years’ experience in senior roles within finance and business development, ranging from large international groups to smaller, entrepreneur-led companies. She has extensive experience of major organisational changes and several initial public offerings, including listings on the Nasdaq Main Market, and currently serves on a number of boards, where she chairs the audit committee.

Johan Lundgren (born 1983) has worked at H&M on several occasions since 2008 and has held roles in sales, business development and operations, both globally and locally. Following a period as Chief Operating Officer at Fortnox, he returned to H&M in 2024, where he is currently responsible for strategy and innovation in his role as Chief Strategy and Innovation Officer.

All of the Nomination Committee's proposals will be presented in the notice to the Annual General Meeting and the proposals and the reasoned statement for the proposed composition of the Board of Directors will also be available on the company's website at the same time.

The Nomination Committee for the 2026 Annual General Meeting consists of Camilla Günesli appointed by Laulima AB, Chair of the Nomination Committee, Karin Cederbaum appointed by Alecta Tjänstepension Ömsesidigt, Björn Henriksson appointed by Nordea fonder, Christopher Beaven appointed by WCM Investment Management, and Cecilia Qvist, Chair of the Board.

For further information, please contact:
Stefan Eriksson, deputy CEO, press & Investor Relations
E-mail: ir@apotea.se

About Apotea
Apotea is Sweden’s leading online pharmacy with the ambition to become the pharmacy of tomorrow by continuously simplifying and enhancing the customer experience. With the widest assortment on the market, low prices and fast deliveries, Apotea facilitates everyday life for its three million active customers. In E-barometern’s 2025 customer survey, Apotea was ranked as the customers’ favourite e-commerce store for the eighth consecutive year. Since 2022, the group also operates in Norway through its Norwegian subsidiary Apotera.

Attachments
The Nomination Committee's proposal for the Board of Directors of Apotea AB (publ)

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.